Digilab BioVisioN GmbH closes cooperation agreement with Boehringer Ingelheim
06-Apr-2006
Within the project Digilab BioVisioN will analyze the quantitative peptide content of biological samples for the German pharmaceutical company. Using the patent-protected Peptidomics®-Technologies of Digilab BioVisioN, differences in peptide patterns are sought in order to identify new biomarkers. Further details of the project were not released.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
DeCODE Discovers Major Genetic Risk Factor for Type 2 Diabetes - Discovery may enable development of diagnostics and drugs of major benefit to public health
Go to page
ETAPHARM chem. pharm. Laboratorium Gesellschaft m.b.H - Wien, Austria
Go to page
biosyn Arzneimittel GmbH - Fellbach, Germany
Go to page
Digoxin
Go to page
Novartis: US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)
Go to page
TGP-Technische Glasblaeserei Paris - Karlsruhe, Germany
Go to page
Study reveals stem cells in a human parasite
Go to page
Syngene International and Innate Pharmaceuticals collaborate to develop virulence blockers
Go to page